A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents
Authors
Keywords
Reversal agents, Protamine, Unfractionated heparin, Low molecular weight heparin, Major bleeding, Delparantag (PMX-60056)
Journal
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
Volume 37, Issue 3, Pages 271-278
Publisher
Springer Nature
Online
2013-05-07
DOI
10.1007/s11239-013-0927-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation
- (2012) S.A. Andrade et al. BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
- Parenteral Anticoagulants
- (2012) David A. Garcia et al. CHEST
- New Antithrombotic Drugs
- (2012) Jeffrey I. Weitz et al. CHEST
- Perioperative Management of Antithrombotic Therapy
- (2012) James D. Douketis et al. CHEST
- The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity
- (2012) E. Condac et al. GLYCOBIOLOGY
- Venous thromboembolism: Annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates
- (2012) Matthew E. Borrego et al. THROMBOSIS AND HAEMOSTASIS
- Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy
- (2011) T. J. Povsic et al. EUROPEAN HEART JOURNAL
- Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients
- (2011) Andrew J. Gale et al. THROMBOSIS RESEARCH
- Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives
- (2010) E. P. Bianchini et al. BLOOD
- First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention
- (2010) Mauricio G. Cohen et al. CIRCULATION
- In Vivo Neutralization of Unfractionated Heparin and Low-Molecular-Weight Heparin by a Novel Salicylamide Derivative
- (2010) Jacqueline Kuziej et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist
- (2010) Daniel J. Cushing et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
- (2010) Martin B. Leon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nonfatal self-poisoning with LMW heparin and the use of antidote
- (2010) Mari A. Bjornaas et al. THROMBOSIS RESEARCH
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients
- (2009) S. SCHULMAN et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Parenteral Anticoagulants
- (2008) Jack Hirsh et al. CHEST
- New Antithrombotic Drugs
- (2008) Jeffrey I. Weitz et al. CHEST
- The Perioperative Management of Antithrombotic Therapy
- (2008) James D. Douketis et al. CHEST
- Antithrombotic Therapy for Venous Thromboembolic Disease
- (2008) Clive Kearon et al. CHEST
- Treatment and Prevention of Heparin-Induced Thrombocytopenia
- (2008) Theodore E. Warkentin et al. CHEST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started